MRI-Guided Biopsies: A Game-Changer for Detecting Clinically Significant Prostate Cancer

Advancements in Prostate Cancer Diagnosis

Minimally Invasive Diagnostic Methods

The ideal diagnostic method for cancer detection is one that is minimally invasive, has minimal side effects, and effectively identifies patients who would benefit from treatment. A recent study published in the New England Journal of Medicine (NEJM) indicates that MRI-guided prostate biopsies result in fewer false positives compared to traditional biopsy methods.

Current Diagnostic Practices

Typically, men suspected of having prostate cancer are identified through elevated prostate-specific antigen (PSA) levels or an abnormal rectal examination. They are subsequently offered a standard transrectal ultrasonography-guided biopsy for diagnosis. However, this approach can be unnecessarily invasive and may lead to over-detection of low-grade and under-detection of high-grade prostate cancers.

The over-detection of low-grade prostate cancer can lead to overtreatment, including radical therapies that come with side effects. Additionally, active surveillance for other men over time can impose substantial costs on both patients and the healthcare system.

Multiparametric MRI as an Alternative

An alternative diagnostic tool that has seen significant improvements over the past decade is multiparametric magnetic resonance imaging (MRI). This technology integrates multiple imaging sequences to enhance tissue differentiation and improve cancer detection and tumor localization in the prostate. Multiparametric MRI has the potential to serve as a triage test, potentially avoiding unnecessary biopsies if results are negative. If the MRI results are positive, it allows for a more targeted biopsy approach to the areas identified as abnormal.

Previous Studies on MRI-Targeted Biopsy

Prior studies, primarily from single centers, have shown that MRI-targeted biopsies yield similar or higher rates of detection for clinically significant prostate cancer while lowering detection rates of clinically insignificant cancer. Given these findings, researchers initiated a large multicenter, randomized trial to evaluate different diagnostic methods.

The PRECISION Trial Overview

The PRECISION trial (Prostate Evaluation for Clinically Important Disease: Sampling Using Image Guidance or Not?) aimed to determine whether multiparametric MRI-guided targeted biopsies are as effective as standard transrectal ultrasonography-guided biopsies in detecting prostate cancer among men suspected of having the disease. The results were published in the NEJM.

The trial involved 500 men with clinical suspicion of prostate cancer who had not undergone a biopsy previously. Participants were randomly assigned to receive either an MRI with or without targeted biopsy or a standard transrectal ultrasonography-guided biopsy. Only those with MRI results indicating the possibility of prostate cancer were offered a targeted biopsy.

Results of the Study

The primary outcome was the proportion of men diagnosed with clinically significant prostate cancer, while the secondary outcome focused on the diagnosis of clinically insignificant cancer. Among the 252 men assigned to the MRI-targeted biopsy group, 28% (71 men) had MRI results suggesting they did not have prostate cancer and therefore did not proceed to biopsy.

The MRI-targeted biopsy group diagnosed fewer cases of clinically insignificant prostate cancer (9%) compared to the standard biopsy group (22%). Moreover, the detection rate for clinically significant prostate cancer was higher in the MRI-targeted biopsy group (38%) than in the standard biopsy group (26%). The use of MRI prior to biopsy resulted in a 12% increase in the detection of clinically significant cancer.

Clinical and Economic Implications

These findings suggest that multiparametric MRI, without a targeted biopsy, is a superior diagnostic method compared to the standard transrectal ultrasonography-guided biopsy. This is particularly significant for men at risk of prostate cancer who have not previously undergone a biopsy. Furthermore, the use of MRI-targeted biopsies is economically favorable, as it reduces unnecessary biopsies and avoids subjecting patients with non-threatening cancers to harmful and costly treatments.

Limitations and Training Requirements

Despite the advantages, researchers noted a limitation regarding the use of MRI as a diagnostic tool. Performing and interpreting high-quality MRI requires specialized skills. Continuous training in technological advancements and changes in health services is essential for clinicians to effectively carry out prostate MRI, thereby increasing accessibility for men suspected of having prostate cancer.

Reference

Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 Mar 18. doi: 10.1056/NEJMoa1801993.